The collaboration centers around Exact Sciences’ Cologuard, the first and only FDA-approved, non-invasive stool DNA screening test for colorectal cancer, according to a news release.
Phillips-Medisize, a Molex company, said the collaboration will seek to focus on the patient experience through the simplicity and convenience of at-home testing. The company developed new tooling to safeguard against inadvertent leaks while meeting specifications and tolerances required to produce the highest levels of product quality.
Exact Sciences was able to utilize supply chain flexibility to acquire all components needed to rapidly scale production of the kit, while Phillips-Medisize located and validated alternate supply sources, conducted risk assessments and forecasting and created sourcing and procurement plans to protect against unplanned disruptions.
Phillips-Medisize also diversified its manufacturing footprint by transitioning a former Molex site in Little Rock, Arkansas, to complement its medical manufacturing sites in Wisconsin, aiding in the collaboration’s efforts to scale for rapid growth.
“We offered Exact Sciences a one-stop shop of advanced manufacturing,” Molex President of Medical & Pharmaceutical Solutions Paul Chaffin said in the release. “From human-factors design, complex molding and reagent handling to volume manufacturing, finished packaging, as well as labeling and serialization, we have everything they needed to bring this innovative product to market. We brought a powerful mix of capabilities and expertise to help Exact Sciences change the game in the fight against colorectal cancer.”